Citation: | MA Jun, CHEN Shu-jun, QIN Yang, et al. In vivo and in vitro Experiment of E74-Like Factor 5 Overexpression Inhibiting the Biological Behavior of Colon Cancer Cells[J]. Journal of Sichuan University (Medical Sciences), 2021, 52(3): 430-437. DOI: 10.12182/20210560207 |
[1] |
HE J H, LI Y G, HAN Z P, et al. The circRNA-ACAP2/HSA-miR-21-5p/TIAM1 regulatory feedback circuit affects the proliferation, migration, and invasion of colon cancer SW480 Cells. Cell Physiol Biochem,2018,49(4): 1539–1550. DOI: 10.1159/000493457
|
[2] |
BA S, XUAN Y, LONG Z W, et al. MicroRNA-27a promotes the proliferation and invasiveness of colon cancer cells by targeting SFRP1 through the Wnt/β-Catenin signaling pathway. Cell Physiol Biochem,2017,42(5): 1920–1933. DOI: 10.1159/000479610
|
[3] |
LUK I Y, REEHORST C M, MARIADASON J M. ELF3, ELF5, EHF and SPDEF transcription factors in tissue homeostasis and cancer. Molecules, 2018, 23(9): 2191[2020-04-11]. https://pubmed.ncbi.nlm.nih.gov/30200227/. doi: 10.3390/molecules23092191.
|
[4] |
CRAIG M P, SUMANA S. ETS transcription factors in embryonic vascular development. Angiogenesis,2016,19(3): 275–285. DOI: 10.1007/s10456-016-9511-z
|
[5] |
SIZEMORE G M, PITARRESI J R, BALAKRISHNAN S, et al. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer,2017,17(6): 337–351. DOI: 10.1038/nrc.2017.20
|
[6] |
SWAHN H, SABITH EBRON J, LAMA K M, et al. Coordinate regulation of ELF5 and EHF at the chr11p13 CF modifier region. J Cell Mol Med,2019,23(11): 7726–7740. DOI: 10.1111/jcmm.14646
|
[7] |
OMATA F, MCNAMARA K M, SUZUKI K, et al. Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients. Breast Cancer,2018,25(4): 489–496. DOI: 10.1007/s12282-018-0842-z
|
[8] |
PIGGIN C L, RODEN D L, GALLEGO-ORTEGA D, et al. ELF5 isoform expression is tissue-specific and significantly altered in cancer. Breast Cancer Res, 2016, 18(1): 4[2020-04-11]. https://pubmed.ncbi.nlm.nih.gov/26738740/. doi: 10.1186/s13058-015-0666-0.
|
[9] |
YAN H C, QIU L L, XIE X L, et al. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells. Oncol Rep,2017,37(3): 1412–1418. DOI: 10.3892/or.2017.5418
|
[10] |
LAPINSKAS E J, SVOBODOVA S, DAVIS I D, et al. The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney. Twin Res Hum Genet,2011,14(4): 316–322. DOI: 10.1375/twin.14.4.316
|
[11] |
YAO B, ZHAO J S, LI Y L, et al. Elf5 inhibits TGF-β-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate,2015,75(8): 872–882. DOI: 10.1002/pros.22970
|
[12] |
CHAKRABARTI R, HWANG J L, ANDRESBLANCO M, et al. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol,2012,14(11): 1212–1222. DOI: 10.1038/ncb2607
|
[13] |
GALLEGO-ORTEGA D, LEDGER A, RODEN D L, et al. ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells. PLoS Biol, 2015, 13(12): e1002330[2020-05-14]. https://pubmed.ncbi.nlm.nih.gov/26717410/. doi: 10.1371/journal.pbio.1002330.
|
[14] |
KALYUGA M, GALLEGO-ORTEGA D, LEE H J, et al. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLoS Biol, 2012, 10(12): e1001461[2020-05-14]. https://pubmed.ncbi.nlm.nih.gov/23300383/. doi: 10.1371/journal.pbio.1001461.
|
[15] |
WU B, CAO X M, LIANG X Z, et al. Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. PLoS One, 2015, 10(1): e0117510[2020-05-14]. https://pubmed.ncbi.nlm.nih.gov/25629735/. doi: 10.1371/journal.pone.
|